JP2022527144A5 - - Google Patents
Info
- Publication number
- JP2022527144A5 JP2022527144A5 JP2021540477A JP2021540477A JP2022527144A5 JP 2022527144 A5 JP2022527144 A5 JP 2022527144A5 JP 2021540477 A JP2021540477 A JP 2021540477A JP 2021540477 A JP2021540477 A JP 2021540477A JP 2022527144 A5 JP2022527144 A5 JP 2022527144A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- car according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025126649A JP2025172739A (ja) | 2019-01-11 | 2025-07-29 | 抗可変ｍｕｃ１＊抗体およびその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791661P | 2019-01-11 | 2019-01-11 | |
| US62/791,661 | 2019-01-11 | ||
| USPCT/US2019/019566 | 2019-02-26 | ||
| PCT/US2019/019566 WO2019165421A1 (en) | 2018-02-26 | 2019-02-26 | Diagnostic methods using anti-muc1* antibodies |
| USPCT/US2019/021556 | 2019-03-11 | ||
| PCT/US2019/021556 WO2019173815A2 (en) | 2018-03-09 | 2019-03-11 | Method for anti-muc1* car t cell stimulation |
| PCT/US2020/013410 WO2020146902A2 (en) | 2019-01-11 | 2020-01-13 | Anti-variable muc1* antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025126649A Division JP2025172739A (ja) | 2019-01-11 | 2025-07-29 | 抗可変ｍｕｃ１＊抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022527144A JP2022527144A (ja) | 2022-05-31 |
| JP2022527144A5 true JP2022527144A5 (enExample) | 2023-04-18 |
Family
ID=71521210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540477A Pending JP2022527144A (ja) | 2019-01-11 | 2020-01-13 | 抗可変ｍｕｃ１＊抗体およびその使用 |
| JP2025126649A Pending JP2025172739A (ja) | 2019-01-11 | 2025-07-29 | 抗可変ｍｕｃ１＊抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025126649A Pending JP2025172739A (ja) | 2019-01-11 | 2025-07-29 | 抗可変ｍｕｃ１＊抗体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12583927B2 (enExample) |
| EP (1) | EP3908603A4 (enExample) |
| JP (2) | JP2022527144A (enExample) |
| CN (2) | CN120484122A (enExample) |
| AU (1) | AU2020205735A1 (enExample) |
| CA (1) | CA3126391A1 (enExample) |
| IL (1) | IL284772A (enExample) |
| WO (1) | WO2020146902A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116199790A (zh) | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| EP3759145A4 (en) * | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES |
| CN120484122A (zh) | 2019-01-11 | 2025-08-15 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| CA3183682A1 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| AU2021316042A1 (en) * | 2020-07-29 | 2023-03-30 | Minerva Biotechnologies Corporation | Anti-variable MUC1* antibodies and uses thereof |
| EP4210733B1 (en) * | 2020-09-04 | 2024-11-06 | Miltenyi Biotec B.V. & Co. KG | System for inducible expression of an adapter in immune cells |
| JP2024541076A (ja) * | 2021-11-09 | 2024-11-06 | ヤンセン バイオテツク，インコーポレーテツド | Ｔ細胞受容体リガンドを特定するためのマイクロ流体共カプセル化デバイス、システム、及び方法 |
| WO2023123195A1 (zh) * | 2021-12-30 | 2023-07-06 | 深圳市先康达生命科学有限公司 | 一种目的基因可调控的工程化免疫细胞及其制备方法和应用 |
| CN119317447A (zh) * | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| WO2023220560A1 (en) * | 2022-05-09 | 2023-11-16 | Minerva Biotechnologies Corporation | Chimeric antigen receptor and il-18 receptor compositions and methods of use therein |
| US20240261406A1 (en) | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
| US20250121088A1 (en) * | 2023-10-11 | 2025-04-17 | Minerva Biotechnologies Corporation | Anti-muc1* antibody drug complexes and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240390418A1 (en) | 1997-09-04 | 2024-11-28 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
| AU3087801A (en) * | 2000-02-04 | 2001-08-14 | Molecular Dynamics Inc | Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| GB0802931D0 (en) * | 2008-02-18 | 2008-03-26 | Queen Mary & Westfield College | Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions |
| EP3130607B1 (en) * | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| JP2012034668A (ja) * | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用 |
| WO2014028668A2 (en) * | 2012-08-14 | 2014-02-20 | Minerva Biotechnologies Corporation | Stem cell enhancing therapeutics |
| WO2015116753A1 (en) | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| AU2015243948B2 (en) | 2014-04-07 | 2020-10-15 | Minerva Biotechnologies Corporation | Anti-NME antibody |
| CN116199790A (zh) * | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| EP3265486A4 (en) * | 2015-03-06 | 2018-11-14 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
| CA3039797A1 (en) | 2016-10-11 | 2018-04-19 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and use of cleavage enzyme |
| US11578115B2 (en) * | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| WO2019104306A1 (en) | 2017-11-27 | 2019-05-31 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| WO2019124468A1 (ja) | 2017-12-24 | 2019-06-27 | ノイルイミューン・バイオテック株式会社 | ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞 |
| JP7416695B2 (ja) | 2017-12-29 | 2024-01-17 | メモリアル スローン－ケタリング キャンサー センター | 増強されたキメラ抗原受容体およびその使用 |
| EP3759145A4 (en) * | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES |
| EP3868783A4 (en) | 2018-10-19 | 2022-01-19 | Cartexell Inc. | ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR THEREOF |
| WO2020116686A1 (ko) | 2018-12-06 | 2020-06-11 | 고려대학교 산학협력단 | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |
| CN120484122A (zh) | 2019-01-11 | 2025-08-15 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| CN110903401A (zh) | 2019-11-20 | 2020-03-24 | 浙江大学 | 一种靶向cd19的二代嵌合抗原受体及其表达载体与应用 |
| AU2021316042A1 (en) | 2020-07-29 | 2023-03-30 | Minerva Biotechnologies Corporation | Anti-variable MUC1* antibodies and uses thereof |
| US20240261406A1 (en) | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
-
2020
- 2020-01-13 CN CN202510558379.6A patent/CN120484122A/zh active Pending
- 2020-01-13 WO PCT/US2020/013410 patent/WO2020146902A2/en not_active Ceased
- 2020-01-13 JP JP2021540477A patent/JP2022527144A/ja active Pending
- 2020-01-13 CN CN202080020073.0A patent/CN113853386A/zh active Pending
- 2020-01-13 AU AU2020205735A patent/AU2020205735A1/en active Pending
- 2020-01-13 EP EP20738367.0A patent/EP3908603A4/en active Pending
- 2020-01-13 CA CA3126391A patent/CA3126391A1/en active Pending
-
2021
- 2021-07-11 IL IL284772A patent/IL284772A/en unknown
- 2021-07-12 US US17/373,609 patent/US12583927B2/en active Active
-
2025
- 2025-07-29 JP JP2025126649A patent/JP2025172739A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527144A5 (enExample) | ||
| JP2021094037A5 (enExample) | ||
| JP2021087455A5 (enExample) | ||
| JP2023537326A5 (enExample) | ||
| JP2019527557A5 (enExample) | ||
| JP2025065142A5 (enExample) | ||
| JP2018525033A5 (enExample) | ||
| FI3334765T3 (fi) | Yksidomeenivasta-aineisiin perustuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2023534808A5 (enExample) | ||
| JP2023059873A5 (enExample) | ||
| JP2020533958A5 (enExample) | ||
| JP2021500881A5 (enExample) | ||
| JP2020114264A5 (enExample) | ||
| JP2022501043A5 (enExample) | ||
| JP2020513754A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| JP2017519502A5 (enExample) | ||
| JP2021514631A5 (enExample) | ||
| KR20190065318A (ko) | 세포에 의해 발현되는 생물학적 활성을 조절하는 결합 분자 | |
| JP2017522893A5 (enExample) | ||
| RU2018109426A (ru) | Химерные антигенные рецепторы со встроенными контролируемыми функциями | |
| JP2022514693A5 (enExample) | ||
| JP2021532742A5 (enExample) | ||
| JP2017527275A5 (enExample) | ||
| JP2023544890A5 (enExample) |